Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Features

Features
Micromet develops new lymphoma therapeutic...KD-247, a promising HIV-neutralizing antibody

20 Jun 06

Todays Headlines from across the DailyUpdates network (19th June - 2006): Today we feature over 60 breaking journal articles including our featured study discussing the development of a new antibody being developed for HIV-1. In addition we highlight news from Micromet on their antibody therapy for the treatment of NHL
LeadDiscovery

CD40:CD40L as a target for Alzheimers...A new candidate oncology therapeutic to enter the clinic

19 Jun 06

In today's edition of DailyUpdates we report on CD40:CD40L. Traditionally a target for autoimmune/transplant therapeutics, we highlight a study supporting the development of blockers of CD40:CD40L as candidate treatments of Alzheimer's disease. We also highlight a new oncology candidate in development by Lorus
LeadDiscovery

Further development of HDAC inhibitors...Novel approaches to the treatment of depression

16 Jun 06

In today's edition of DailyUpdates we headline with news from CuraGen and TopoTarget on a new trial evaluating the combination of an HDAC inhibitor an cis-retinoid acid. In addition we highlight research from Wyeth suggesting a new approach to depression
LeadDiscovery

Erbitux: emerging data at ASCO reveal potential to further exploit benefits of the targeted EGFR therapy in mCRC

14 Jun 06

Data presented at the American Society of Clinical Oncology (ASCO) meeting in Atlanta this month suggest that administering the epidermal growth factor receptor (EGFR) inhibitor Erbitux (cetuximab) fortnightly rather than weekly in metastatic colorectal cancer (mCRC) is a feasible option. Another study probing whether scaling up the dose, to the point where patients experience the significant rash linked to long survival, achieves a better response, shows high doses are well tolerated.
Olwen Glynn Owen - PharmiWeb Field Reporter

Vertex: next-generation hepatitis drugs within reach

12 Jun 06

Vertex has launched a major phase II clinical trial to test a new hepatitis C drug candidate, with a second trial scheduled to begin in June. This is a significant advance in the development of much-needed treatments for hepatitis C. By drawing parallels with similar HIV treatments, Datamonitor's Morris Paterson outlines the pitfalls and prospects for this new drug.
Datamonitor Expert Views

Advances in diabetes...combating the menace of HIV/Tuberculosis co-infection

12 Jun 06

Today's edition highlights news from Metabolex announcing the initiation of a Phase 2/3 trial of a novel insulin sensitizer, metaglidasen. In addition we discuss research published by Advanced Life Sciences who are making exciting breakthroughs moving towards the treatment of HIV Tuberculosis co-infection which has become a global catastrophe.
LeadDiscovery

Targeting Ubiquitin For Drug Discovery & Development

10 Jun 06

Breakthroughs in our understanding of the Ubiquitin system are increasingly being routed towards clinical applications. Targeting Ubiquitin for Drug Discovery and Development conference has assembled leaders from industrial and academic research to discuss the state of the art and prospects for the future. With the FDA approval and commercialization of Velcade, scientists are now beginning to see the potential of this ever expanding science. New therapeutic targets are being explored and implica
Seth Fritts

Merck wins the race for HPV vaccine approval in the US...CRP inhibitor shows promise as a cardioprotective agent

09 Jun 06

Today we report on the FDA approval of Merck's HPV vaccine, the first such vaccine to be approved in the US; and a candidate treatment for various cardiovascular diseases
LeadDiscovery

Stimuvax, first therapeutic vaccine for lung cancer, to start Phase III trial

08 Jun 06

Stimuvax (L-BLP 25), a therapeutic vaccine in development for non-small cell lung cancer (NSCLC), should enter Phase III testing this autumn. The START (Stimulating Targeted Antigenic Response to NSCLC Trial ) plans to recruit over 1300 patients with stage III unresectable disease from more than 140 centres in North America and Europe. Patients will receive an initial round of chemo/radiation therapy and if they show a response, or exhibit stable disease, they will be randomised in a ratio of 2:
Olwen Glynn Owen - PharmiWeb Field Reporter

Losartan, a stimulator of insulin release?

08 Jun 06

DailyUpdates 2nd June: In today’s edition of DailyUpdates we highlight exciting new data on the potential use of the antihypertensive, losartan as a modulator of insulin release and production and hence a directly acting therapeutic for the treatment of diabetes. This supplements additional beneficial activity resulting from blood pressure control. In addition we report on European approval of Thelin, Encysive’s candidate for the treatment of pulmonary hypertension
LeadDiscovery

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.